Ipsen is participating in three phase III studies conducted under the auspices of the International Breast Cancer Study Group for the treatment of premenopausal breast cancer. These studies compare conventional treatment methods with hormone therapy combining Decapeptyl® with estrogen suppressor agents. They are scheduled to continue through to 2015. Their findings could lead to a revision of treatment guidelines for breast cancer in pre-menopausal women expressing hormonal receptors.
Tasquinimod is being developed jointly with Active Biotech (Sweden). Tasquinimod is an oral compound quinoline-3-carboxamide derivative that binds to a molecule called S100A9. It has demonstrated antiangiogenic, anti-metastatic and immunomodulatory properties. The development of tasquinimod is currently focused on the treatment of advanced metastatic castration resistant prostate cancer.